(PR) UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder

The MarketWatch News Department was not involved in the creation of this content.-- Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a stati ...

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in co ...
The Malaysian Reserve

UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder

Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a statistically significant reduction in countable motor seizure ...
Investopedia

What Is an Assay and How Investors Think About It?

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...